New Results
Cell morphological profiling enables high-throughput screening for PROteolysis TArgeting Chimera (PROTAC) phenotypic signature
Maria-Anna Trapotsi, Elizabeth Mouchet, Guy Williams, Tiziana Monteverde, Karolina Juhani, Riku Turkki, Filip Miljković, Anton Martinsson, Lewis Mervin, Erik Müllers, Ian Barrett, Ola Engkvist, Andreas Bender, Kevin Moreau
doi: https://doi.org/10.1101/2022.01.17.476610
Maria-Anna Trapotsi
1Department of Chemistry, Centre for Molecular Informatics, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK
7Data Sciences & Quantitative Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
Elizabeth Mouchet
2High Throughput Screening, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Macclesfield, UK
Guy Williams
2High Throughput Screening, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Macclesfield, UK
Tiziana Monteverde
2High Throughput Screening, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Macclesfield, UK
Karolina Juhani
2High Throughput Screening, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Macclesfield, UK
Riku Turkki
3Data Sciences & Quantitative Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Filip Miljković
4Imaging and Data Analytics, Clinical Pharmacology & Safety Sciences R&D, AstraZeneca, Gothenburg SE-43183, Sweden
Anton Martinsson
4Imaging and Data Analytics, Clinical Pharmacology & Safety Sciences R&D, AstraZeneca, Gothenburg SE-43183, Sweden
Lewis Mervin
5Molecular AI, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
Erik Müllers
6Bioscience Cardiovascular, Research and Early Development, Cardiovascular, Renal and Metabolism, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Ian Barrett
7Data Sciences & Quantitative Biology, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Cambridge, UK
Ola Engkvist
8Molecular AI, Discovery Sciences, BioPharmaceuticals R&D, AstraZeneca, Gothenburg, Sweden
Andreas Bender
1Department of Chemistry, Centre for Molecular Informatics, University of Cambridge, Lensfield Road, Cambridge, CB2 1EW, UK
Kevin Moreau
9Safety Innovation, Clinical Pharmacology and Safety Sciences R&D, AstraZeneca, Cambridge, UK
Article usage
Posted January 18, 2022.
Cell morphological profiling enables high-throughput screening for PROteolysis TArgeting Chimera (PROTAC) phenotypic signature
Maria-Anna Trapotsi, Elizabeth Mouchet, Guy Williams, Tiziana Monteverde, Karolina Juhani, Riku Turkki, Filip Miljković, Anton Martinsson, Lewis Mervin, Erik Müllers, Ian Barrett, Ola Engkvist, Andreas Bender, Kevin Moreau
bioRxiv 2022.01.17.476610; doi: https://doi.org/10.1101/2022.01.17.476610
Cell morphological profiling enables high-throughput screening for PROteolysis TArgeting Chimera (PROTAC) phenotypic signature
Maria-Anna Trapotsi, Elizabeth Mouchet, Guy Williams, Tiziana Monteverde, Karolina Juhani, Riku Turkki, Filip Miljković, Anton Martinsson, Lewis Mervin, Erik Müllers, Ian Barrett, Ola Engkvist, Andreas Bender, Kevin Moreau
bioRxiv 2022.01.17.476610; doi: https://doi.org/10.1101/2022.01.17.476610
Subject Area
Subject Areas
- Biochemistry (11703)
- Bioengineering (8722)
- Bioinformatics (29127)
- Biophysics (14932)
- Cancer Biology (12048)
- Cell Biology (17359)
- Clinical Trials (138)
- Developmental Biology (9406)
- Ecology (14143)
- Epidemiology (2067)
- Evolutionary Biology (18268)
- Genetics (12220)
- Genomics (16766)
- Immunology (11841)
- Microbiology (28005)
- Molecular Biology (11552)
- Neuroscience (60808)
- Paleontology (450)
- Pathology (1864)
- Pharmacology and Toxicology (3231)
- Physiology (4939)
- Plant Biology (10384)
- Synthetic Biology (2877)
- Systems Biology (7333)
- Zoology (1642)